Printer Friendly
The Free Library
14,715,855 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Subset analysis.


In addition to the primary study question, SMART will generate data for subset analysis on quality of life, cost effectiveness, HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States.  transmission risk behavior, and probably metabolic complications. Data for a given subset analysis will be gathered only from those sites preselected for the particular question.

1) Quality of life. Antiretroviral therapy can suppress viral load viral load
n.
The concentration of a virus, such as HIV, in the blood.


viral load,
n a measure of the number of virus particles present in the bloodstream, expressed as copies per milliliter.
 and raise CD4 T cell Noun 1. CD4 T cell - T cell with CD4 receptor that recognizes antigens on the surface of a virus-infected cell and secretes lymphokines that stimulate B cells and killer T cells; helper T cells are infected and killed by the AIDS virus  counts; however, treatment often produces side effects Side effects

Effects of a proposed project on other parts of the firm.
 and toxicity (e.g. nausea, diarrhea, neuropathy, etc.) that decrease quality of life. Therefore, quality of life may decline after the initiation of treatment for the patient with early, asymptomatic disease. This subanalysis will examine the long-term impact of early versus deferred initiation of therapy and the stage of HIV disease on quality of life. It will also examine the impact of uninterrupted versus episodic therapy on quality of life.

2) Cost. The treatment of HIV disease is expensive and antiretroviral drugs Antiretroviral Drugs Definition

Antiretroviral drugs inhibit the reproduction of retroviruses—viruses composed of RNA rather than DNA. The best known of this group is HIV, human immunodeficiency virus, the causative agent of AIDS.
 are a large part of the cost. However, the treatment of opportunistic infections Opportunistic infections

Infections that cause a disease only when the host's immune system is impaired. The classic opportunistic infection never leads to disease in the normal host.
, which may require hospitalization, is also expensive. If a treatment approach reduces the use of antiretrovirals but raises the number of infections, it could be more costly in the long run than using more antiretrovirals. This subanalysis will examine the treatment costs of SMART's 2 arms.

3) HIV transmission risk behavior. With reports of drug resistance among persons with acute HIV infection, attention has focused on the role that HIV-infected patients under care play in the ongoing transmission of HIV. This subanalysis will examine the effect that deferring or discontinuing therapy has on HIV transmission risk behavior and the effect of viral load on risk behavior.

4) Metabolic complications. The metabolic complications of antiretroviral therapy, including a potentially increased risked for cardiovascular disease and changes in body habitus habitus /hab·i·tus/ (hab´i-tus) [L.]
1. attitude (2).

2. physique.


hab·i·tus
n. pl.
, may be severe enough to warrant delay in the start of therapy. This subanalysis will evaluate the effect of the 2 treatment strategies on the development of metabolic complications. An examination of metabolic complications may be structured as an actual substudy, but a final decision whether to run a subanalysis or substudy had not been made at press time.
COPYRIGHT 2001 The Center for AIDS: Hope & Remembrance Project
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:research on long-term effects of antiretroviral therapy
Publication:Research Initiative/Treatment Action!
Article Type:Brief Article
Geographic Code:1USA
Date:Mar 22, 2001
Words:350
Previous Article:Some statistical background on SMART.(research on long-term effects of antiretroviral therapy)(Brief Article)
Next Article:Time and Events Schedule for the Main SMART Study.(research on the long-term effects of antiretroviral therapy)(Brief Article)
Topics:



Related Articles
In for the long haul: debate paves way for long-term trials(*).
Activists demand new research agenda.
SMART: background, concepts, and design.(research on long-term effects of highly active antiretroviral therapy)
Some statistical background on SMART.(research on long-term effects of antiretroviral therapy)(Brief Article)
Time and Events Schedule for the Main SMART Study.(research on the long-term effects of antiretroviral therapy)(Brief Article)
Time to get SMART.(research on long-term effects of antiretroviral therapy)
Too smart for our own good.(HIV treatment research)
Tenofovir: FDA Hearing October 3, Public Comment Deadlines September 26.
Tenofovir approved: Broad indication.(Brief Article)
Major study of "discordant" response--viral control but incomplete CD4 response.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles